Patents Assigned to Randox Laboratories Limited
-
Publication number: 20120283127Abstract: The present invention provides an ex vivo method for aiding the diagnosis of Alzheimer's disease in a patient, the method comprising the steps of determining the level of expression of at least four platelet proteins in a platelet sample from the patient selected from monoamine oxidase-B, coagulation factor Xllla, total tropomyosin (a and 13), WD-repeat protein 1 and apolipoprotein E4; and comparing the result of (i) to a control value, wherein a result higher than the control value is indicative of Alzheimer's disease. Preferably, the method of the invention further comprises determining the level of expression of wild-type GSTO-1 or mutant GSTO-1.Type: ApplicationFiled: December 3, 2010Publication date: November 8, 2012Applicant: Randox Laboratories LimitedInventors: Ellen Umlauf, Maria Zellner
-
Publication number: 20120208213Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.Type: ApplicationFiled: December 20, 2011Publication date: August 16, 2012Applicant: RANDOX LABORATORIES LIMITEDInventors: Elouard Benchikh, Stephen Peter Fitzgerald, Paul John Innocenzi, Philip Andrew Lowry, Ivan Robert McConnell
-
Publication number: 20120164756Abstract: The invention describes a method for monitoring and detecting non-therapeutic, therapeutic and toxic concentrations of aspirin in individuals which uses the urinary salicylic acid to salicyluric acid ratio.Type: ApplicationFiled: June 9, 2010Publication date: June 28, 2012Applicant: RANDOX LABORATORIES LIMITEDInventors: Elouard Benchikh, Stephen Peter Fitzgerald, Philip Andrew Lowry, Paul John Innocenzi, Ivan Robert McConnell
-
Publication number: 20120040378Abstract: Carisoprodol is a centrally-acting prescription drug of known abuse. Upon ingestion it is rapidly metabolised to meprobamate, also a prescription drug with abuse potential. Current immunoassays are specific for carisoprodol and therefore have a short window of detection and, furthermore, are ineffective at detecting meprobamate. The current invention, underpinned by an antibody specific for meprobamate, overcomes these deficiencies.Type: ApplicationFiled: August 9, 2011Publication date: February 16, 2012Applicant: RANDOX LABORATORIES LIMITEDInventors: Elouard Benchikh, Ivan McConnell, Peter Fitzgerald, Philip Lowry
-
Publication number: 20120003674Abstract: The invention relates to an immunoassay method and kit for the indirect detection of chloral hydrate. The invention is underpinned by a novel immunogen that produces an antibody that is specific for the chloral hydrate metabolite trichloroethanol glucuronide. Detection and quantification of trichloroethanol glucuronide has important applications in clinical toxicology, drug facilitated crime, water testing and solvent exposure.Type: ApplicationFiled: June 29, 2011Publication date: January 5, 2012Applicant: Randox Laboratories LimitedInventors: Elouard Benchikh, Ivan McConnell, Peter Fitzgerald, Philip Lowry
-
Publication number: 20110183317Abstract: The present invention provides an in vitro method for determining the resistance or sensitivity of a cell line or patient sample to a deoxyribonucleoside kinase-dependent drug, wherein the method comprises the steps of: (i) treating a patient sample or cell line, or a portion thereof, with a deoxyribonucleoside kinase-dependent drug; (ii) lysing the cells of the patient sample or cell line from step (i); (iii) optionally, mixing a portion of the cell lysate from step (ii) with a bioluminescent reporter bacteria incorporating a gene coding for deoxyribonucleoside kinase; (iv) mixing a portion of the cell lysate from (ii) with a bioluminescent reporter bacteria incorporating a gene coding for a deoxyribonucleoside kinase and a deoxyribonucleoside kinase transcription promoter; (v) mixing a portion of the cell lysate from step (ii) with a bioluminescent reporter bacteria incorporating a gene coding for a deoxyribonucleoside kinase, a deoxyribonucleoside kinase transcription promoter and a dephosphorylating agentType: ApplicationFiled: August 10, 2009Publication date: July 28, 2011Applicants: RANDOX LABORATORIES LIMITED, UNIVERSITY OF THE WEST OF ENGLANDInventors: Vyvyan Clare Salisbury, Habib Mahmoud Alloush, Margaret Ann Smith, Paul John Innocenzi, Mark William Ruddock, Ashley Diane Martin
-
Patent number: 7811824Abstract: A method of monitoring the properties of a biological or chemical sample. The method includes carrying out a plurality of different tests on the sample to generate corresponding test data; optionally carrying out a preliminary processing of the test data to generate partially processed data; storing the test data and/or partially processed data; causing a processing system to analyze a user-defined selection of the test data or partially processed data to generate result data relating to one or more properties of the sample; and subsequent to the previous step, receiving a second user defined selection of the test data or partially processed data, different from the first selection, and causing the processing system to analyze the second user-defined selection of the test data or partially processed data to generate second result data relating to one or more properties of the sample different from the properties corresponding to the first user-defined selection.Type: GrantFiled: March 30, 2006Date of Patent: October 12, 2010Assignee: Randox Laboratories LimitedInventors: John Victor Lamont, Robert Ivan McConnell, Stephen Peter Fitzgerald
-
Patent number: 7371829Abstract: The invention provides haptens, immunogens comprising such haptens coupled to an antigenicity-conferring carrier material, conjugates comprising such haptens bonded to a labelling agent as well as, antibodies raised against such immunogens and capable of binding with ketamine and its primary metabolite, norketamine.Type: GrantFiled: January 31, 2003Date of Patent: May 13, 2008Assignee: Randox Laboratories LimitedInventors: Robert Ivan McConnell, Elouard Benchikh, Stephen Peter Fitzgerald, John Victor Lamont
-
Publication number: 20070238181Abstract: A method of monitoring the properties of a biological or chemical sample.Type: ApplicationFiled: March 30, 2006Publication date: October 11, 2007Applicant: RANDOX LABORATORIES LIMITEDInventors: John Lamont, Robert McConnell, Stephen Fitzgerald
-
Patent number: 7217802Abstract: The invention provides a hapten, an immunogen comprising the hapten coupled to an antigenicity-conferring carrier material, a conjugate comprising the hapten coupled to a labelling agent, as well as, antibodies raised against the aforementioned immunogen and capable of binding with MDMA.Type: GrantFiled: December 20, 2002Date of Patent: May 15, 2007Assignee: Randox Laboratories LimitedInventors: Robert Ivan McConnell, Elouard Benchikh, Stephen Peter Fitzgerald, John Victor Lamont
-
Publication number: 20070072242Abstract: The invention provides haptens, immunogens comprising such haptens coupled to an antigenicity-conferring carrier material, conjugates comprising such haptens bonded to a labelling agent as well as, antibodies raised against such immunogens and capable of binding with leucomalachite green and malachite green.Type: ApplicationFiled: September 21, 2006Publication date: March 29, 2007Applicant: Randox Laboratories LimitedInventors: Elouard Benchikh, Robert McConnell, Stephen Fitzgerald, Andrew Lowry
-
Publication number: 20060223132Abstract: The present invention relates to a method for preparing haptens of formulae I and II that are useful in the preparation of immunogens, antibodies and conjugates, for use in competitive immunoassays for the detection of ractopamine, isoxsuprine and ritodrine. The haptens are prepared by reacting a phenylethanolamine derivative of formula D with a phenylalkylcarbonyl derivative of formula E: in which, in formula I, Z1 is a crosslinker and Z2 is H and, in formula II, Z1 is H and Z2 is a crosslinker.Type: ApplicationFiled: November 10, 2005Publication date: October 5, 2006Applicant: Randox Laboratories LimitedInventors: Robert McConnell, Stephen Fitzgerald, El Benchikh, Andrew Lowry
-
Patent number: 6960653Abstract: The invention provides a hapten comprising a 6-[D-?-aminoacetamido] penicillin derivative crosslinked at the ?-amino group with a substituted or unsubstituted phenyldicarbaldehyde. In addition, the invention provides an immunogen comprising the aforementioned hapten coupled to an antigenicity-conferring carrier material, a conjugate comprising the aforementioned hapten coupled to a labelling agent, as well as, antibodies raised against the aforementioned immunogen and capable of binding with at least one structural epitope of an intact ?-lactam ring.Type: GrantFiled: July 31, 2002Date of Patent: November 1, 2005Assignee: Randox Laboratories LimitedInventors: Robert Ivan McConnell, Elouard Benchikh, Stephen Peter Fitzgerald, John Victor Lamont
-
Patent number: 6881572Abstract: An assay device incubator comprises a housing (46) defining a region within which at least one assay device is located in use, the housing defining laterally opposed sidewalls (48, 50) of at least one bay (33) in which an assay device can be located. The housing (46) includes one or more guides (49, 51) for supporting the assay device and enabling the assay device to undergo to and fro movement therealong. A vibration system (40, 60) is coupled to the at least one tray in use for vibrating the tray to and fro along the or each guide. A heating system (70) heats the region within the housing.Type: GrantFiled: April 4, 2003Date of Patent: April 19, 2005Assignee: Randox Laboratories LimitedInventors: Stephen Peter Fitzgerald, John Victor Lamont, Robert Ivan McConnell
-
Publication number: 20030224447Abstract: The invention provides haptens, immunogens comprising such haptens coupled to an antigenicity-conferring carrier material, conjugates comprising such haptens bonded to a labelling agent as well as, antibodies raised against such immunogens and capable of binding with ketamine and its primary metabolite, norketamine.Type: ApplicationFiled: January 31, 2003Publication date: December 4, 2003Applicant: Randox Laboratories LimitedInventors: Robert Ivan McConnell, Elouard Benchikh, Stephen Peter Fitzgerald, John Victor Lamont
-
Publication number: 20030215367Abstract: An assay device incubator comprises a housing (46) defining a region within which at least one assay device is located in use, the housing defining laterally opposed sidewalls (48, 50) of at least one bay (33) in which an assay device can be located. The housing (46) includes one or more guides (49, 51) for supporting the assay device and enabling the assay device to undergo to and fro movement therealong. A vibration system (40, 60) is coupled to the at least one tray in use for vibrating the tray to and fro along the or each guide. A heating system (70) heats the region within the housing.Type: ApplicationFiled: April 4, 2003Publication date: November 20, 2003Applicant: Randox Laboratories LimitedInventors: Stephen Peter Fitzgerald, John Victor Lamont, Robert Ivan McConnell
-
Publication number: 20030170728Abstract: The invention provides an immunogen comprising a hapten coupled to an antigenicity-conferring carrier material, a conjugate comprising the aforementioned hapten coupled to a labelling agent, as well as, antibodies raised against the aforementioned immunogen and capable of binding with at least one structural epitope of metabolites of fentanyl and of metabolites of fentanyl analogs.Type: ApplicationFiled: November 15, 2002Publication date: September 11, 2003Applicant: Randox Laboratories LimitedInventors: Robert Ivan McConnell, Elouard Benchikh, Stephen Peter Fitzgerald, John Victor Lamont
-
Patent number: 6551851Abstract: A method of manufacturing a diaphragm utilising a precision grinding technique after etching a cavity in a wafer. A technique for preventing distortion of the diaphragm based on use of a sacrificial layer of porous silicon is disclosed.Type: GrantFiled: June 18, 2001Date of Patent: April 22, 2003Assignee: Randox Laboratories LimitedInventors: Harold S Gamble, S J Neil Mitchell, Andrzej Prochaska, Stephen Peter Fitzgerald
-
Publication number: 20030071235Abstract: A passive microvalve comprises a substrate having a first aperture. An upper plate is mounted on the substrate and has a second aperture opening into a space defined between the substrate and the upper plate. A closure member is mounted in the space and is movable between a first position in which it allows fluid flow between the first and second apertures and a second position in which it closes the second aperture.Type: ApplicationFiled: September 20, 2002Publication date: April 17, 2003Applicant: RANDOX LABORATORIES LIMITEDInventors: Harold Samuel Gamble, Samuel John Neil Mitchell, Daniel Chia Sheng Bien, Stephen Peter Fitzgerald
-
Patent number: D668780Type: GrantFiled: July 26, 2011Date of Patent: October 9, 2012Assignee: Randox Laboratories LimitedInventors: Gareth Wilson, Carl Wrigglesworth